For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 37,187 | |||
| General and administrative | 10,612 | |||
| Total operating expenses | 47,799 | |||
| Loss from operations | -47,799 | |||
| Grant income | 23,406 | |||
| Other income, net | 919 | |||
| Interest expense | -13 | |||
| Total other income, net | 24,312 | |||
| Net loss | -23,487 | |||
| Total comprehensive loss | -23,487 | |||
| Basic EPS | -0.32 | |||
| Diluted EPS | -0.32 | |||
| Basic Average Shares | 72,766,983 | |||
| Diluted Average Shares | 72,766,983 | |||
COGNITION THERAPEUTICS INC (CGTX)
COGNITION THERAPEUTICS INC (CGTX)